Skip to content
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Menu
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Pipeline
SurVaxM
Clinical Trials
About
Leadership Team
News
Contact
Read more about the article US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma

US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma

  • Post author:mimivax
  • Post published:May 30, 2024
  • Post category:Uncategorized

US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma

Continue ReadingUS FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma

Recent Posts

  • US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma
  • MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
  • MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma 
  • MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology
  • Phase 2a Trial of SurVaxM Plus Temozolomide for Newly Diagnosed Glioblastoma

Recent Comments

    Archives

    • May 2024
    • January 2024
    • October 2023
    • December 2022
    • November 2022
    • February 2022
    • November 2021
    • November 2019
    • October 2019
    • May 2019
    • March 2018
    • August 2017
    • July 2016
    • September 2015
    • April 2015

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    MimiVax, Inc.

    [email protected]

    Elm & Carlton Streets
    Buffalo, NY 14263

    Back to top
    Twitter Linkedin Youtube
    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.I agree